COSM Cosmos Health Inc.
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand. It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.…
Industry Peers
Medical DistributionKey Statistics
About Cosmos Health (NASDAQ: COSM)
›
Cosmos Health (NASDAQ: COSM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Distribution industry, part of the Healthcare sector, and reports about 163 employees.
The shares were at 3.240 USD on 13 November 2026, up 343.8% over 52 weeks. Its 52-week range is 0.1620 USD to 4.350 USD: the price is 25.5% below the high and 1900.0% above the low.
Its market capitalisation is 16.30M USD.
Cosmos Health reports return on equity of -103.9%, an operating margin of -24.6% and revenue up 28.8% year over year.
Its debt exceeds its cash by 14.14M USD, a debt-to-equity ratio of 1.08. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 2.950 USD is 9.0% below the current price.